CLINICAL RESEARCH
The molecular significance of BRCA1 promoter methylation in peripheral blood cells in women with breast cancer in West Algeria
1
Department of Biology, Nature and Life Sciences Faculty, University of Oran 1 Ahmed Ben Bella, Oran, Algeria
2
Laboratory of Biology of Development and Differentiation (LBDD), Department of Biology, Nature and Life Sciences Faculty, University of Oran 1 Ahmed Ben Bella, Oran, Algeria
Submission date: 2024-07-24
Acceptance date: 2024-08-13
Publication date: 2024-09-10
Corresponding author
Souhila Belkacem Hacherfi
Department of Biology Nature and Life Sciences Faculty University of Oran 1 Ahmed Ben Bella BP 1524 EL M’naouer Oran 31000, Algeria
Department of Biology Nature and Life Sciences Faculty University of Oran 1 Ahmed Ben Bella BP 1524 EL M’naouer Oran 31000, Algeria
Arch Med Sci Civil Dis 2024;9(1):7-13
KEYWORDS
breast cancerBRCA1 promoter methylationperipheral blood cellsmethylation specific PCRwestern Algeria
TOPICS
ABSTRACT
Introduction:
Epigenetic alterations, in particular DNA methylation, are the most important mechanism that silences tumor suppressor genes during carcinogenesis. Methylation of the BRCA1 promoter in peripheral blood is associated with an increased risk of breast cancer. In the present study, we aimed, for the first time in western Algeria, to investigate the role of BRCA1 CpG promoter methylation in peripheral blood cells (PBCs) among breast cancer patients, as a potential biomarker for detecting breast cancer risk at an early age.
Material and methods:
The methylation profile of the BRCA1 gene promoter and its frequency in PBCs, derived from 39 breast cancer patients, was explored by methylation-specific PCR (MSPCR). The association between methylation profiles and clinicopathological features was evaluated with SPSS statistics software to estimate a convenient biomarker for early detection of breast cancer.
Results:
MSPCR results demonstrated that the methylation frequency of the BRCA1 gene promoter detected in PBCs is significantly higher than in other populations. It was observed in 23 of 39 (58.97%) breast cancer patients.
Conclusions:
Our study showed that the methylation of the BRCA1 gene promoter detected in PBCs’ DNA could have potential utility in clinical diagnostics as a new biomarker for breast cancer risk in Algerian women and for early detection.
Epigenetic alterations, in particular DNA methylation, are the most important mechanism that silences tumor suppressor genes during carcinogenesis. Methylation of the BRCA1 promoter in peripheral blood is associated with an increased risk of breast cancer. In the present study, we aimed, for the first time in western Algeria, to investigate the role of BRCA1 CpG promoter methylation in peripheral blood cells (PBCs) among breast cancer patients, as a potential biomarker for detecting breast cancer risk at an early age.
Material and methods:
The methylation profile of the BRCA1 gene promoter and its frequency in PBCs, derived from 39 breast cancer patients, was explored by methylation-specific PCR (MSPCR). The association between methylation profiles and clinicopathological features was evaluated with SPSS statistics software to estimate a convenient biomarker for early detection of breast cancer.
Results:
MSPCR results demonstrated that the methylation frequency of the BRCA1 gene promoter detected in PBCs is significantly higher than in other populations. It was observed in 23 of 39 (58.97%) breast cancer patients.
Conclusions:
Our study showed that the methylation of the BRCA1 gene promoter detected in PBCs’ DNA could have potential utility in clinical diagnostics as a new biomarker for breast cancer risk in Algerian women and for early detection.
REFERENCES (10)
1.
Ferlay J, Ervik M, Lam F, et al. (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today.
2.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
4.
Lian ZQ, Wang Q, Li WP, Zhang AQ, Wu L. Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels. Int J Oncol 2012; 41: 629-38.
5.
Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18: 1957-65.
6.
Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000; 21: 1761-5.
7.
Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
8.
Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCAI accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9: 444-50.
9.
Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 2003; 5: 45-52.
10.
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-82.
Share
RELATED ARTICLE
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
